Contribute Try STAT+ Today

If the U.S. wants to effectively combat high drug costs and make medicines affordable, the federal government needs to take several aggressive, if controversial steps, according to a sweeping and ambitious report from the National Academies of Sciences, Engineering, and Medicine.

The recommendations include a bevy of familiar notions:

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • No matter how long and how many days the drug pricing is discussed there are two conflicting facts that prevent lower drug prices. One is profits and the other is pharma companies capitalizing on human desire/weakness to extend life at all costs. Another fact no one wants to discuss is lobbying effort where politicians are bought and sold to assure drug prices stay high.

    Pharma uses inefficient processes to produce drugs and their is no effort to improve processes as the regulators interfere. They have a task to assure quality is maintained but companies at times cut corners. Companies won’t agree with what I am saying but in the name of profits shortcuts are way of life in manufacturing.

    Only way prices can be lowered is price control.

  • Won’t denying tax deductions for direct-to-consumer drug advertising actually cause drug manufacturers to pass on more marketing costs to consumers in the form of higher drug prices? I wish there was more talk about banning direct-to-consumer prescription drug advertising entirely, the costs of which already contribute to higher drug prices. The United States and New Zealand are the only industrialized nations in which such advertising is not banned.

    • Hi Elizabeth,
      Thanks for your note. The report is very lengthy, but if you dig in, there is mention of encouraging industry to end direct to consumer advertising. There would like be a free speech fight if Washington were to attempt to regulate this, but the issue was noted.
      ed at pharmalot

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy